Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Table 4 Logistic regression analyses of objective response

Variables	Univariate		Multivariate
Variables	Odds ratio (95% CI)	p-value	Odds ratio (95% CI)	p-value
Age, ≥ 65 years	0.63 (0.32–1.24)	0.181
Sex, men	0.80 (0.38–1.71)	0.562
Smoking, ever-smoker	0.71 (0.33–1.53)	0.380
ECOG-PS*
0 vs. 1	1.53 (0.72–3.35)	0.272	1.25 (0.56–2.83)	0.585
0 vs. ≥ 2	5.35 (1.39–35.37)	0.012	2.09 (0.43–15.28)	0.373
1 vs. ≥ 2	3.50 (0.82–24.28)	0.094	1.67 (0.33–12.51)	0.548
Charlson comorbidity index*
0 vs. 1	1.04 (0.48–2.31)	0.927
0 vs. ≥ 2	1.64 (0.57–5.47)	0.371
1 vs. ≥ 2	1.58 (0.48–5.80)	0.457
GNRI, ≥ 92	4.28 (1.76–12.11)	< 0.001	3.25 (1.22–9.97)	0.018
Pathology, squamous cell (vs. non-squamous)	0.68 (0.30–1.47)	0.331
Stage, IIIb (vs. IV/ recurrent)	1.15 (0.42–2.98)	0.779
Platinum agents, cisplatin (vs. carboplatin)	1.49 (0.65–3.39)	0.345
Non-platinum agents*
Pemetrexed vs. taxane	1.61 (0.77–3.41)	0.541	1.46 (0.68–3.20)	0.334
Pemetrexed vs. others	2.67 (1.03–7.59)	0.044	2.17 (0.80–6.41)	0.131
Taxane vs. others	1.65 (0.62–4.78)	0.319	1.49 (0.53–4.44)	0.455
Treatment year, 2011–2020 (vs. 2000–2010)	1.77 (0.89–3.59)	0.104

CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, GNRI Geriatric Nutritional Risk Index, N.E. not estimated
*Odds ratio was calculated for each pair of three categorical units

ISSN: 1471-2466